|
Mary L. Anderson is Vice President Business Development. Ms. Anderson joined XOMA in February 2008. She is responsible for overseeing XOMA's business development initiatives including licensing activities related to XOMA's therapeutic pipeline support of the antibody collaborations business the licensing of the company's antibody technologies and the advancement of biodefense programs.
Ms. Anderson has 20 years of experience in the pharmaceutical and biotechnology industry. Prior to joining XOMA she served as the Executive Director Global Licensing and Business Development for Oncology at Merck-Serono a global biopharmaceuticals company where she led the in-licensing of multiple clinical stage oncology products and was a key member of the team responsible for the approximately $15 billion acquisition of Serono SA.
Before her experience at Merck-Serono Ms. Anderson was Senior Director Corporate Development at MorphoSys where she was charged with growing the antibody discovery business. She also held business development positions at Agensys and Bayer. Trained in biochemistry Ms. Anderson spent her early years in research at Chiron and Gen-Probe. She received a Masters degree in business administration from St. Mary's College of California and a Bachelor of Science degree in biochemistry from California Polytechnic State University at San Luis Obispo. | 